Cargando…

Case series: rituximab in the treatment of refractory sight-threatening scleritis

Detalles Bibliográficos
Autores principales:	van Bilsen, Kiki, van Hagen, P Martin, Missotten, Tom, Baarsma, Seerp G, Kuijpers, Robert W, van Laar, Jan AM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242238/ http://dx.doi.org/10.1186/1479-5876-9-S2-P12

Ejemplares similares

Somatostatin receptor scintigraphy in sarcoidosis
por: Kamphuis, Lieke SJ, et al.
Publicado: (2011)

FcRn mediated IgG transport by retinal pigment epithelium cells
por: Korthagen, Nicoline M, et al.
Publicado: (2012)

Efficacy and maintenance of rituximab treatment in non‐infectious scleritis
por: Vergouwen, Daphne P. C., et al.
Publicado: (2021)

The neonatal Fc receptor is expressed by human lymphocytes
por: van Bilsen, K, et al.
Publicado: (2010)

Efficacy of adalimumab in sarcoidosis
por: Kamphuis, LSJ, et al.
Publicado: (2010)

Commentary: Rituximab in scleritis
por: Dutta Majumder, Parthopratim
Publicado: (2020)

P36 A case of refractory IBD-related scleritis
por: Paterson-Brown, Lucy, et al.
Publicado: (2021)

Tofacitinib in Refractory Scleritis: A Case Series
por: Dey, Suvankar, et al.
Publicado: (2023)

Combined Infliximab and Rituximab in Necrotising Scleritis
por: Morarji, Jiten, et al.
Publicado: (2012)

Rituximab for non-infectious Uveitis and Scleritis
por: Ng, Caleb C., et al.
Publicado: (2021)

Basophil Activation Test in the prediction of anaphylactic reactions against Hymenoptera venom in patients suffering from Systemic Mastocytosis
por: Rietveld, Mark JA, et al.
Publicado: (2012)

Rituximab is effective in the treatment of nephritis in lupus patients, refractory to conventional immunosuppressive therapy
por: Martínez, R, et al.
Publicado: (2010)

25. Use of rituximab in refractory primary antiphospholipid syndrome with pulmonary and cerebral manifestations
por: Khan, Asim, et al.
Publicado: (2019)

Infliximab for the treatment of refractory scleritis
por: Doctor, Priyanka, et al.
Publicado: (2009)

Tofacitinib for refractory uveitis and scleritis
por: Paley, Michael A., et al.
Publicado: (2018)

Off-label use of rituximab in refractory pediatric rheumatic diseases: a single-center experience
por: Aguiar, Francisca, et al.
Publicado: (2014)

Distal renal tubular acidosis in primary Sjögren syndrome
por: Both, Tim, et al.
Publicado: (2012)

Characteristics and Outcomes of Patients with Scleritis in the IRIS® Registry (Intelligent Research in Sight) Database
por: Armbrust, Karen R., et al.
Publicado: (2022)

High-dose chemotherapy and syngeneic stem cell transplantation in a patient with refractory rheumatoid arthritis: poor response associated with persistence of synovial abnormalities
por: van Oosterhout, M, et al.
Publicado: (2005)

Safety and efficacy of rituximab in refractory pediatric Systemic Lupus Erythematosus nephritis: a single-center experience of northern Greece
por: Trachana, M, et al.
Publicado: (2011)

Diagnosis and treatment of uveitis; not restricted to the ophthalmologist
por: van Laar, Jan A. M., et al.
Publicado: (2015)

O28 A rare sight-threatening complication of a rare disease
por: Chakravorty, Mithun, et al.
Publicado: (2021)

Refractory necrotizing scleritis successfully treated with adalimumab
por: Lawuyi, Lola E., et al.
Publicado: (2016)

The value of the fore-sight(TM) monitor in the postoperative phase after congenital cardiac surgery. a descriptive statistical interim-analysis
por: Delrue, HGJ, et al.
Publicado: (2015)

Functional regulatory immune responses against human cartilage glycoprotein-39 in health versus proinflammatory responses in rheumatoid arthritis
por: van Bilsen, JHM, et al.
Publicado: (2005)

Treatment of refractory juvenile dermatomyositis with tacrolimus
por: Hassan, J, et al.
Publicado: (2008)

4. A challenging case of refractory BehÇet's disease in an adolescent with sight threatening uveitis
por: Cooper, Gisella, et al.
Publicado: (2018)

Propofol and thiopental for refractory status epilepticus in children
por: van Gestel, S, et al.
Publicado: (2005)

The effect of Rituximab treatment on T cells
por: Diaz-Torné, C, et al.
Publicado: (2010)

Mast cells are major contributors to the pathophysiology of Graves’ Ophthalmopathy (GO)
por: Van Steensel, L, et al.
Publicado: (2010)

54. Binocular sight loss: uncommon, yet a devastating complication of GCA
por: Borukhson, Liubov, et al.
Publicado: (2019)

Monocyte, macrophage and mast cell-derived PDGF control inflammation, tissue remodelling and autoimmunity in the pathophysiology of Graves’ ophthalmpathy
por: van Steensel, Leendert, et al.
Publicado: (2011)

P32 Relapsing polychondritis with anterior scleritis in young female
por: Arain, Umair, et al.
Publicado: (2021)

Rituximab for treatment of severe lupus nephritis
por: Baskin, E, et al.
Publicado: (2008)

Dealing with cultural diversity during the process of communication and decision-making in the ICU: a literature review
por: Van Keer, RV, et al.
Publicado: (2014)

Understanding and managing sight-threatening diabetic retinopathy
por: Yorston, David
Publicado: (2023)

Decompressive (hemi)craniectomy for refractory intracranial hypertension after traumatic brain injury
por: van Veen, E, et al.
Publicado: (2006)

Use of Rituximab in child with SLE and myocardial involvement
por: Balan, S, et al.
Publicado: (2008)

Safety of rituximab in children with auto-immune diseases
por: Bader-Meunier, B, et al.
Publicado: (2008)

Seronegative and seropositive rheumatoid arthritis treated with rituximab
por: Velloso Feijoo, Maria Luisa, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_i4eki9ek5ss3bmhmfg0engr5e5